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Abstract 
 
Introduction 
Patients who present with locally advanced inoperable non-small cell lung cancer (NSCLC) may be 
suitable for radical radiotherapy. A randomised trial of 563 patients compared CHART and 
conventional radical radiotherapy (60Gy/30f) given over 6 weeks and suggested that CHART resulted 
in a 9% improvement in 2-year survival1. RT dose escalation for both conventional and CHARTWEL 
(CHART-WeekEndLess) - fractionation schedules is feasible with modern 3-dimensional CT-based 
planning techniques and we initiated a phase I CHART dose escalation study in 2009. Methods 
Patients with WHO performance status 0-2 histologically confirmed, inoperable, stage I-III non-small 
cell lung cancer were recruited into an open phase I dose escalation trial. Three cohorts of six patients 
were recruited sequentially. Total dose was escalated from standard CHART radiotherapy of 54 
Gy/36f/12 days to 57.6Gy (2 x 1.8 Gy fractions on day 15, Group 1), 61.2Gy (4 x 1.8 Gy fractions on 
days 15-16, Group 2) and 64.8Gy (6 x 1.8 Gy fractions on days 15-17, Group 3). 
Results 
Between April 2010 and May 2012, 18 patients were enrolled from 5 UK centres and received 
escalated dose radiotherapy. 14 were male, 16 squamous cell histology and 12 were stage IIIA or IIIB. 
The median age was 70 years and baseline characteristics were similar across the three dose cohorts.  
One patient did not start escalated radiotherapy but all remaining patients completed their planned 
radiotherapy schedules.  Of these 9 patients have died to date with a median survival of 2 years across 
the three cohorts. Grade 3 or 4 adverse events (fatigue, dysphagia, nausea and anorexia ± classified 
according to the National Cancer Institute Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0) were reported in 6 patients but the pre-specified dose limiting toxicities (grade 4 
early oesophagitis; grade 3 cardiac, spinal cord and pneumonitis) were not observed.  
 
Conclusions 
CHART remains a radiotherapy schedule in routine use across the UK and in this dose escalation study 
no dose limiting toxicities were observed. We feel the  dose of 64.8Gy / 42f / 17 days should be taken 
forward into further clinical trials.  The sample size used in this study was small so we plan a 
randomised phase II study that includes other radiotherapy schedules to confirm safety and select an 
accelerated sequential chemo-radiotherapy schedule to take into phase III studies.  
 
 
 
 
 
 
 
 
  
  
Introduction 
 
Lung cancer is the leading cause of cancer mortality worldwide with approximately 38,000 
new cases diagnosed annually in the UK alone2.   Non-Small Cell Lung Cancer (NSCLC) 
accounts for approximately 80% of all lung cancers.  The majority of cases are inoperable at 
presentation due to medical co-morbidity (stages I, II and III NSCLC), or tumour extent 
(stages III and IV NSCLC).  Although many patients with stage I-III disease can still be 
treated radically using radiotherapy the 5 year survival from lung cancer in the UK has 
changed little (from 3% to 8%) over the last 60 years. The poor outcome can be related to 
both failure to eradicate local disease and the development of distant metastases. 
Bronchoscopic re-evaluation after radical thoracic RT has demonstrated persistent tumour in 
85% of cases3.  Successful local control has been found to correlate with improved survival,4.  
Approaches to achieve better local control include the acceleration of the RT schedule, the 
addition of radio-sensitizers and dose escalation4-6. 
 
Concurrent chemo-radiotherapy (CTRT) (chemotherapy and RT given at the same time) is the 
standard of care in stage III NSCLC4 with median survival rates of approximately 21 months. 
However, the majority of patients are not suitable for this treatment based on poor 
performance status and co-morbidities7. The alternative treatment offered to patients who are  
unsuitable for concurrent CTRT is sequential CTRT (chemotherapy given prior to RT), but 
local control rates are inferior when compared to concurrent CTRT which is reflected in 
worse survival rates4. Alternative strategies to achieve improved local control by intensifying 
the local anti-tumour effect are needed. 
 
In the UK the Continuous Hyper-fractionated Accelerated Radiation Therapy (CHART) trial 
intensified local treatment by accelerating the RT course.  The investigators delivered 54Gy 
using 1.5Gy fractions 3 times per day for 12 consecutive days (including weekends) and 
demonstrated an overall survival advantage when compared with the standard fractionation 
regimen in use at that time (60Gy in 30 daily fractions over 6 weeks)1.  There was a 9% 
absolute improvement in 2 year survival (29% v 20%; p=0.004) for CHART with no evidence 
of a difference in acute or long-term toxicity.  This result is supported by an individual patient 
data meta-analysis6 confirming that CHART and other intensified schedules which accelerate 
or hyper-fractionate improve overall survival as compared to conventional fractionation, with 
an absolute benefit of 3% at 5 years. CHART is currently recommended as the standard 
radical RT schedule for treating NSCLC in the UK8.  Despite this improvement in overall 
survival, persistent local disease remains the main cause of death in patients who received 
CHART.   
 
  
RT dose escalation for conventional and the accelerated CHARTWEL fractionation schedules 
was shown to be feasible with 3-dimensional CT-based planning techniques9-10. The initial 
dose escalation studies delivered additional daily fractions of radiotherapy and the recently 
completed RTOG 0617 11 study has shown no benefit for dose escalation with a prolonged 
treatment schedule. This study compared 60 to 74Gy and reported patients in the higher dose 
arm suffered higher local relapse rates and inferior survival compared to the control arm.  
 
The RTOG study result is refocusing interest on acceleration and hypo-fractionation and 
techniques that avoid prolongation of the overall treatment time are attractive as they reduce 
the impact of accelerated tumour clonogen proliferation, which becomes clinically relevant 
for NSCLC at least 3-4 weeks after initiation of radiotherapy12. Studies have shown that dose 
escalation using 3-D conformal hypo-fractionated radiotherapy is feasible13,14 and the 
application of extreme hypo-fractionation associated with stereotactic ablative radiotherapy 
(SABR) has delivered impressive local control when used for early NSCLC patients15. 
However, when treating central tumours the toxicity rates associated with SABR were 
excessive16. Due to the short overall duration of the standard CHART schedule, it is possible 
to dose escalate by introducing additional days of treatment and still complete therapy before 
the period of accelerated tumour repopulation is expected to begin.  This study reports dose 
escalation beyond standard CHART performed in a stepped approach using additional twice 
daily 1.8Gy fractions. 
 
  
Methods and materials 
 
Patients and study design 
When the study was designed a pragmatic decision was taken not to give the additional 
radiotherapy fractions outside the standard working hours for the radiotherapy departments. 
Radiobiological advice guided us to use twice daily 1.8 Gy fractions estimating that the 
maximum tolerated dose for oesophagus would be around 65 Gy given over 18 days. 
 
Patients had to have histologically or cytologically confirmed stage I-III non-small cell lung 
cancer, with disease deemed inoperable disease by a Lung Cancer Multi-Disciplinary Team 
(MDT) with input from Thoracic Surgeon, or operable but the patient refuses surgery. 
Patients had to be previously untreated with chemotherapy or radiotherapy, have ECOG 
performance status 0 or 1, a life expectancy of at least 6 months, be free of any malignancy 
likely to interfere with protocol treatment or comparisons, have adequate respiratory function 
(i.e. forced expiratory volume in one second (FEV1) or transfer factor (DLCO) of greater than 
40% predicted), and be considered suitable for CHART. 
 
Pre-trial entry, patients had an up to date clinical assessment of eligibility, which included 
PET-CT, pulmonary function tests, ECG, Haematology and biochemistry tests (with a brain 
scan if required) performed within 42 days of trial registration. Baseline patient characteristics 
were collected, and then participating centres telephoned the Scottish Clinical Trials Research 
Unit, who allocated patients to one of the treatment cohorts. Patients attended for CHART 
radiotherapy planning as soon as possible after registration and on confirmation that the plan 
would meet the normal tissue dose constraints the patient attended for treatment verification 
and to consent to enter the trial. 
 
Radiotherapy Treatment Planning 
All patients were 3D-conformally planned and treated in the supine position, with arms 
supported above the head with an external immobilisation device. A single phase technique 
was used, without elective nodal irradiation. A planning CT scan using continuous 2.5 - 5mm 
slices was acquired throughout the entire volume of both lungs in the treatment position. 
Treatment was planned with full information from bronchoscopy, CT-PET and, if performed, 
mediastinoscopy or thoracotomy and 3D conformal RT planning used inhomogeneity 
correction. Treatment planning aimed to optimise the dose distribution to allow dose 
escalation and dose volume histograms (DVH) were constructed for the planning target 
volume (PTV), oesophagus, heart, whole lung minus gross tumour volume (GTV), and spinal 
cord.   
  
Gross Tumour Volume (GTV) included the primary tumour mass and involved nodes, defined 
as nodes with short axis > 10 mm or showing increased uptake on PET-CT. Clinical Target 
Volume (CTV) is arrived by expansion of GTV by a 5 mm. Planning Tumour Volume (PTV) 
is arrived by expansion of CTV by a 10 mm margin (15 mm margin in the cranial caudal 
direction).  Dose was calculated using type B algorithms and prescribed to the ICRU 
reference point. The specified dose constraints were -  
 
CTV Minimum dose > 95% of prescribed dose 
PTV V (95% of prescribed dose) > 90% 
Cord Maximum dose < 44Gy 
Whole Lung-GTV V (20Gy)  < 35% 
Oesophagus Maximum dose < 105% of prescribed dose 
Heart V (100% of prescribed dose) < 30% V (50% of prescribed dose) < 50% 
 
Simulation and electronic portal images (EPIs) were used to confirm the accuracy of 
treatment to within 5mm with set-up should be adjusted according to local guidelines when 
discrepancy was PP 
 
Radiotherapy Quality Assurance 
Radiotherapy Quality Assurance (QA) was a requirement for all participating centres, and 
was administered by a central QA group. The QA process built on that developed for the 
INCH17 and CONVERT18 trials in collaboration with the NCRI QA group based at Mount 
Vernon Hospital. Prior to entering patients centres had to complete a questionnaire covering 
immobilisation and planning imaging, planning parameters, commissioning the treatment 
planning system, and treatment delivery facilities. Each clinician had to submit a patient plan 
and accreditation was only granted once the QA group had approved the plan. Subsequently 
each local radiotherapy team had to complete a delineation exercise and each centre was 
visited in order to perform dosimetric and portal imaging QA using phantoms.   
 
Statistical analysis 
The dose escalation schedule was - 
Group 1 57.6Gy in 38 fractions, treating 8 hours apart on day 15 (CHART 
plus 2 x 1.8 Gy fractions on day 15) 
Group 2 61.2Gy in 40 fractions, treating 8 hours apart on days 15-16 (CHART 
plus 4 x 1.8 Gy fractions on days 15-16) 
Group 3 64.8Gy in 42 fractions, treating 8 hours apart on days 15-17 (CHART 
plus 6 x 1.8 Gy fractions on days 15-17) 
 
  
Six patients were recruited sequentially into each Group, providing that the following dose 
limiting toxicity (DLT, classified according to the National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.0) were not met at the previous 
dose level: 
 
Pneumonitis:  Grade 3 or above: More than one patient (out of six) 
Cardiac Toxicity: Grade 3 or above: More than one patient (out of six) 
Spinal Cord Toxicity: Grade 3 or above: More than one patient (out of six) 
Oesophagitis (Early): Grade 4 or above: More than one patient (out of six) 
 
The maximum tolerated dose (MTD) was defined as the dose level below which > 1/6 or > 
2/12 patients experience a DLT. If these DLT rates are not observed then the top dose will be 
recommended. 
When 6 patients had been recruited into each of the groups, review ensured that the maximum 
oesophageal dose lay within +/- 5% of the prescribed dose in at least 4 patients before 
recruitment proceeded to the next dose level. If dose limiting levels of toxicity were reported 
for one patient, a further 6 patients were recruited at that dose level to expand the group. 
Recruitment was interrupted following completion of each group, until at least 4 patients had 
been followed up for 2 months to ensure that any early oesophageal reactions had settled.  If 
one or more patients developed late pulmonary toxicity of Grade 3 or higher then recruitment 
into the CHART-ED study would end.  
Data were analysed on an intention to treat basis regardless of any deviation from the 
protocol. Survival was measured from the date of first treatment until the date of death from 
any cause, with surviving patients censored at the date of their last assessment. 
 
Trial Governance 
The trial was approved by the Oxford A Medical Research Ethics Council (MREC), and all 
patients provided written informed consent. The trial was conducted in compliance to the 
principles outlined in the Medical Research Council Good Clinical Practice (MRC GCP) 
guidelines and the Data Protection Act (DPA G0027154) and other regulatory requirements. 
 
  
Results 
 
Nineteen patients were recruited into the study, one received the standard CHART dose and 
fractionation but did not receive the planned dose escalation on day 15. This patient  in cohort 
three, suffered an exacerbation of COPD as the CHART schedule was being completed. A 
further patient was recruited to this cohort and all other patients received the planned 
radiotherapy treatment on schedule. The baseline demographical details are recorded in Table 
1, and radiotherapy planning details summarised in table 2.  
 
 
No patient experienced the pre-specified dose limiting toxicities though 6 patients did report 
grade 3 ± 4 adverse events (fatigue 3, dysphagia 3, anorexia 3 and nausea 1). Figure 1 shows 
the doses received by the oesophagus and acute oesophagitis was documented in 17 of the 
patients treated, generally grade I ± II but three patients required iv hydration (Grade 3 
oesophagitis). Late oesophageal toxicity has been limited to grade I/II in 5 patients. Grade I 
pulmonary pneumonitis / fibrosis was documented (clinically or radiologically) in 12 patients 
across the three cohorts and no cardiac or spinal cord toxicity was reported though one 
cardiac arrest was documented 12 months after completion of radiotherapy.   
 
 
A tumour response was documented in 11/18patients (61%) across the cohorts (complete 
response in 5/18 (28%) patients and a further 5 patients had stable disease on post-treatment 
CT scans. After a median follow up time of 21 months (range 1 ± 36) 8 patients had relapsed, 
3 with only loco-regional progression.Nine patients were alive and had their data censored 
when the study closed; 8 patients dying of disease related causes during the study and the 
remaining patients death was not disease related. Overall 2 year survival was 49% and 42% of 
patients were alive and progression free at 2 years.  Overall survival curves are shown in 
Figure 2 with no significant differences seen between the three cohorts.  
 
Limitations 
 
As there were no dose limiting toxicities reported the study did not need to expand any of the 
dose cohorts which limited recruitment to 19 patients during the 25 months the study was 
open. This is a much smaller number than the number of eligible patients seen in the centres 
recruiting to the study giving the potential for selection bias to influence some of the 
treatment outcomes like survival.  
 
 
  
Discussion 
 
Despite considerable effort over the last few decades, there has been little improvement in 
survival for NSCLC when compared to other sites such as breast and colorectal cancers. 
Many reasons are documented for patients not receiving radical surgery or concurrent chemo-
radiotherapy treatment7 but in the vast majority it is due to co-morbidity, insufficient 
respiratory function or poor performance status. Stereotactic ablative body radiotherapy 
(SABR) has been developed as a treatment option for early NSCLC and is providing proof of 
principle evidence for accelerated dose escalation. Over the past 5 years the published 
evidence for SABR has increased19,20 and consistently shows impressive local control rates of 
around 90% at 5 years, with evidence that this contributes to improved outcomes across a 
population21. However, there is little published randomised trial data comparing SABR with 
µFRQYHQWLRQDOO\¶ IUDFWLRQDWHG UDGLRWKHUDS\, and the data presented has yet to show superior 
outcomes with SABR22.  
 
Van Baardwijk et al have performed a systematic review that extends the SABR information 
E\LQFOXGLQJGDWDIURPKLJKGRVHµFRQYHQWLRQDO¶UDGLRWKHUDS\VHULHVdelivered using schedules 
lasting around 4 weeks157KHVHDFFHOHUDWHGµFRQYHQWLRQDO¶WUHDWPHQWVDOVRUHSRUWJRRGORFDO
control in stage I disease with a local relapse figure of 13%, and we should remember the 
median survival of 25.2 months documented for CHART treatment of stage 1A and 1B 
disease23 is consistent with that reported in these publications. The significant toxicities seen  
when SABR was used for more central tumours16 is an additional reason to continue to 
develop accelerated schedules for the treatment of stage III disease where mediastinal 
radiotherapy will need to be given.   
 
Meta-analysis has confirmed that accelerated or hyper-fractionated radiotherapy schedules6 
improve local control and survival when compared to conventionally fractionated treatments 
(64-66Gy in 32-33 fractions), with a Hazard Ratio of 0.88 equating to a 2.5% improvement in 
5 year survival. Recent NICE (National Institute for Health and Clinical Excellence) 
guidance8 SHUFHLYHV &+$57 DV D ³JROG VWDQGDUG´ radiotherapy schedule and Din et al24 
showed that CHART results can be reproduced in daily practice with the short schedule time 
being popular with patients 99% of whom  complete treatment and less than 1% suffering 
grade 4 / 5 toxicity. However, the fact remains that 61% of patients who received CHART 
died with persistent local disease1.   
 
Therefore, it is important to explore dose escalation using both CHART and other 
radiotherapy schedules. The recently completed RTOG 061711 study used a standard arm of 
60Gy in 30 fractions and reported no benefit from  dose escalation to 74Gy in 37 daily 
fractions, and patients in the higher dose arm suffered higher local relapse rates and inferior 
  
survival compared to the control arm. While we can take the median survival of over 24 
months in the standard arm to reflect contemporary practice in terms of patient selection 
(routine use of PET) and the availability of third and fourth line therapies for relapsed disease, 
we have to conclude that dose escalation that extends the treatment schedule is very unlikely 
to lead to any significant gains in outcomes.  
 
However, radiobiological modelling suggests that dose escalation to improve the Tumour 
Control Probability (TCP) is likely to be more effective if the overall treatment time is fixed 
rather that the dose per fraction25. While designing this study we applied similar TCP 
modelling26 to tentatively predict 30 month local progression free survival when treating a 
tumour size of around 150 cc. TCPs of 14% and 20% were calculated for 60 Gy given 
conventionally over 6 weeks and for CHART, the CHART study itself reporting 12 and 18% 
local control at 3 years1.  These calculations also suggested that the CHART-ED schedule 
delivering 64.8 Gy would achieve a TCP of 47%, which compares favourably to the TCP of 
42% calculated for concurrent chemo-radiotherapy delivering 66 Gy using conventional 
fractionation. Since the radiobiological modelling suggested that the 64.8 Gy dose would have 
a significant effect on local control probability we took the decision not to escalate further 
even though the study did not reach a MTD for the oesophagus. 
   
The Meta-analysis by LePechoux et al 6 indicated the benefit of accelerated fractionation is 
not confined to the CHART schedule and dose escalation of other schedules should lead to 
significantly higher rates of local control than those seen with conventional fractionation. 
However, the results from the CHARTWEL study where the dose was escalated to 60 Gy 
failed to show improvement in local control feeding through to any overall survival benefits27. 
The difference in outcomes reported for CHART and CHARTWEL could be a matter of 
statistical chance, but factors relating to the overall length of the treatment schedule may also 
be in play as induction chemotherapy was routinely given prior to radiotherapy in the 
CHARTWEL study 27. In addition, subgroup analysis28 from this study does point toward 
improved outcomes for the accelerated schedule in populations of patients with the larger 
tumours where you might expect to see the most benefit.  
When this study was designed, volume effects had not been demonstrated as clearly for 
oesophagitis as for pneumonitis. We used a volumetric dose constraint for lung, limiting V20Gy 
to a maximum of 35% to control the rates of pneumonitis and lung fibrosis29,30, and relied on 
the incrementally increasing (57.6-64.8 Gy) prescribed dose limit to control oesophageal 
toxicity. A time factor has been demonstrated for early mucosal reactions31,32, and we 
calculated the extension of CHART to the more protracted 18 day schedule should allow 
higher oesophageal doses to be delivered. The maximum point cord dose in the CHART - ED 
  
schedule was also limited to 44 Gy to allow for incomplete repair of normal tissue between 
RT fractions, a concern for schedules delivering three fractions each day.  
 
The majority of patients included in our study have locally advanced  NSCLC, for which neo-
adjuvant, concomitant and adjuvant chemotherapy have well documented survival benefits. 
Consequently combined treatment is commonly recommended for this group of patients. 
Meta-analysis established the benefits and toxicities for conventionally fractionated 
radiotherapy, and the comparison of sequential with concurrent treatment produces a hazard 
ratio in favour of the concurrent treatment (0.84, 95% CI 0.74 ± 0.95)4  and median survivals 
of 24 months would now be expected in the PET staged population11.  
 
It needs to be remembered that the potential toxicity from the concurrent approach can be 
significant, with population based studies showing that performance status, age and co-
morbidities exclude a high number of patients from the concurrent form of treatment7. The 
feasibility of adding induction chemotherapy to CHART has also been demonstrated by the 
INCH trial17, results from which suggest this approach is associated with less toxicity than 
concurrent schedules.  
 
It is in this group of patients, unsuited to concurrent chemo-radiotherapy, that the approach of 
sequential chemo-radiotherapy using dose escalated, accelerated radiotherapy schedules can 
be studied further. The UK has a depth of experience in the use of accelerated fractionations, 
and in addition to CHART-ED dose escalation to 64.8 Gy, similar studies for a dose-escalated 
30 fraction five week concurrent CRT schedule (IDEAL-CRT)33, and 4 week sequential CRT 
schedules (I-START, and Iso-IMRT) are recruiting or has just completed their recruitment. 
Our TCP modeling yields similar calculated TCP values (40-50%) when each of these 
schedules are used to deliver sequential CRT. We aim to carry out a randomized phase II trial 
that compares these schedules which will give some comparative data on the hypo- vs 
hyperfractionated approach for acceleration and aims to identifying the most appropriate dose 
escalated, accelerated sequential chemo-radiotherapy schedule to take into  a phase III trial.   
 
  
 
Used as a single modality treatment the CHART schedule remains a strong alternative to 
conventionally fractionated regimes for patients unsuitable for chemotherapy. The dose 
escalated CHART schedule is feasible and we saw no dose limiting toxicities up to a dose of 
64.8 Gy in 42 fractions over 18 days. Given with sequential chemotherapy this schedule could 
be developed as an alternative in patients unable to undergo concurrent chemo-radiotherapy. 
We plan to take the CHARTED schedule into randomized phase II studies against dose 
escalated accelerated sequential chemo-radiotherapy schedules to establish the optimum 
method of delivering these accelerated radiotherapy regimens in the multi-modality treatment 
setting.  
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Table 1 
Demographic details for patients recruited to the CHART-ED study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Overall  Group 1  Group 2  Group 3 
    (n=18) (N=6) (N=6)  (N=6)  
Median age   70   66  74  74 
Range   44-84  44-78  63-84  64-84 
 
Males   14   4  6  4 
 
Histology  
Squamous   16  5  6  5 
Adenocarcinoma  2  1  0  1 
Other   0  0  0  0 
 
Stage  1-B  1  0  1  0 
(V7)  2A / B 5  1  2  2 
  IIIA   8  4  2  2 
  IIIB   4  1  1  2 
 
WHO PS    0  4  2  1  1 
         1  13  4  5  4 
         2  1  0  0  1 
 
Respiratory Function 
Median FEV1 2.3  1.9  2.0  2.4 
Range  1.1 to 3.6 1.1 to 3.6 1.4 to 2.6 1.6 to 2.9 
Median FVC  3.5  3.0  3.3  3.5 
Range  1.7 to 5.4 1.7 to 5.4 2.3 to 3.8 2.4 to 3.7  
Median DLCO 6.4  6.4  5.5  8.4 
Range  1.7 to 12.0 1.7 to 12.0 3.4 to 7.4 3.8 to 8.9  
 
  
 
Table 2 
Radiotherapy planning data for patient who received a dose escalated 
schedule 
 
 
 
 
Group 1 
(n=6) 
Group 2 
(n=6) 
Group 3 
(n=6) 
All patients 
(n=18) 
% coverage of Mean 89.4 93.6 97.4 93.5 
PTV  by 95% Std dev 8.6 7.4 1.7 7.1 
isodose Maximum 97.5 100.0 99.5 100.0 
  
Minimum 74.7 79.5 94.9 74.7 
 
 
    
% whole lung Mean 25.3 23.2 27.6 25.4 
V20 (Gy) Std dev 7.2 5.0 5.7 6.0 
  
Maximum 33.6 29.7 34.5 34.5 
  
Minimum 13.1 16.2 21.3 13.1 
  
 
    
Maximum  Mean 34.6 33.4 36.2 34.7 
dose to spinal Std dev 8.0 6.5 5.6 6.5 
cord (Gy) Maximum 39.6 43.5 42.1 43.5 
  
Minimum 18.9 25.2 26.4 18.9 
  
 
    
Gross tumour Mean 87.7 84.5 94.4 88.9 
volume (GTV) 
(cm3) 
Std dev 59.1 73.0 77.9 66.3 
  
Maximum 192.0 219.0 212.6 219.0 
  
Minimum 18.5 29.0 18.0 18.0 
  
 
    
Planning Mean 495.5 485.7 521.7 500.9 
target volume Std dev 206.7 234.0 188.3 198.4 
(PTV) (cm3) Maximum 795.0 897.0 733.0 897.0 
  
Minimum 208.0 281.0 278.0 208.0 
 
 
    
Oesophageal 
dose +/- 5% of  
 5 patients 5 patients 5 patients  
prescribed      
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Figure 1 
Plots showing the percentages of outlined oesophagus receiving doses in excess of (a) 95% 
and (b) 100% of the prescribed dose for the 18 patients treated on CHART-ED  
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Figure 2. Survival graphs: overall and by dose escalation cohorts.  
 
 
 
  
 
 
